GLP-1 Medication Label & International Risk Disclosure Analyzer

Target GLP-1 Formulation Semaglutide (Ozempic/Wegovy)

U.S. FDA Prescribing Text

The U.S. label mentions changes in vision under warnings: "Tell your healthcare provider if you have changes in vision during treatment with OZEMPIC®." It does not explicitly state NAION or optic nerve infarction risk.

Regulatory Status: Under Ongoing Safety Review Explicit NAION Warning: No (Generalized Vision Warning Only)

Multi-Agency Cross-Border Comparison Matrix

Jurisdiction	Agency	NAION Warning	Gastroparesis Warning	Clinical Action Advised
United States	FDA	No Specific NAION (Broad Vision)	General GI Delay	Monitor baseline vision changes
European Union	EMA	Explicit Black Triangle / Label	Severe Dehydration & Renal Risk	Immediate ophthalmology consult & stop drug
United Kingdom	MHRA	Explicit Drug Safety Update	Post-marketing Gastroparesis	Urgent evaluation on painless visual loss
Australia	TGA	Product Information Update	Gastrointestinal adverse warning	Disc-at-risk screening & prompt referral

Active Federal Litigation Tracker

Over 1,200 federal lawsuits consolidated in MDL (Gastroparesis & Vision Loss)

Consolidated in In re: Glucagon-like Peptide-1 Receptor Agonists Products Liability Litigation (MDL 3094). Claims center on failure to warn patients of gastroparesis and sudden ischemic vision impairment.

Patient Risk-Factor Self-Assessment

Model personalized risk indicators based on clinical predisposing factors (anatomic crowded optic disc, retinopathy, and metabolic factors).

Patient Age: 54

54 yrs

Clinical History & Indicators Pre-existing Diabetic Retinopathy (Microvascular vulnerability) History of Vision Issues / Crowded Disc (Optic nerve anatomy) History of Gastrointestinal Motility Disorders (Gastroparesis)

Physician Consultation Report

Dynamic clinical briefing formatted for informed consent and healthcare provider discussions.

Loading consultation preview...

Primary Regulatory & Legal Sources:

Wall Street Journal: Patients Sue GLP-1 Drugmakers Over Risk of Sudden Vision Loss (Reporting on international label divergence).
Therapeutic Goods Administration (TGA Australia): GLP-1 RAs and rare vision disorder (NAION) Product Information updates (2025/2026).
European Medicines Agency (EMA): Product characteristics warning update on non-arteritic anterior ischaemic optic neuropathy for semaglutide.
U.S. Judicial Panel on Multidistrict Litigation: MDL No. 3094 - In re: GLP-1 Receptor Agonists Products Liability Litigation.